Peer mentor-reported self-efficacy | N | Mean | SD | p Value | Effect size |
---|---|---|---|---|---|
Peer mentor self-efficacy scale ratings | |||||
Baseline (T1) | 9 | 7.91 | 1.18 | ||
Post-training (T2) | 9 | 9.14 | 0.56 | 0.01* | 1.04 |
End of programme (T3) | 9 | 7.55 | 0.97 | 0.26 | −0.31 |
3 months after programme completion (T4) | 9 | 7.88 | 0.59 | 0.86 | −0.03 |
Mentees’ mean outcome scores at baseline (T1) and programme completion (T2) | |||||
Measurement | N | T1 | T2 | T1–T2 (SD) | Effect size T1–T2 (mean) |
Medication adherence (Morisky scale) | 8 | 0.78 | 0.63 | 0.53 | 0 |
Self-efficacy scale | 8 | 7.59 | 7.75 | 1.01 | 0.04 |
Arthritis Impact Measurement Scales (AIMS2)—Short Form (SF) | |||||
▸ AIMS2-SF | 5 | 30.26 | 28.96 | 1.33 | 0.39 |
▸ AIMS2-Physical (/10) | 8 | 8.36 | 8.60 | 1.98 | 0.19 |
▸ AIMS2-Symptoms (/10) | 8 | 2.59 | 1.56 | 2.23 | 0.28 |
▸ AIMS2-Affect (/10) | 8 | 5.56 | 5.31 | 1.03 | 0.27 |
▸ AIMS2-Social (/10) | 8 | 5.76 | 5.47 | 0.93 | 0.47 |
▸ AIMS2-Work (/10) | 5 | 7.66 | 8.13 | 2.05 | 0.42 |
Coping Efficacy (Gignac et al) | 8 | 4.08 | 4.41 | 0.46 | 0.35 |
Clinical Disease Activity (CDAI) | 6 | 9.94 | 5.68 | 3.91 | 0.19 |
Medical Outcomes Study Social Support Survey (MOSSS) | 8 | 3.77 | 4.11 | 0.28 | 0.30 |
Patient Activation Measure (PAM) | 8 | 75.80 | 73.11 | 11.75 | 0.22 |